ProCE Banner Activity

ASCEND: 4-Yr Follow-up Analysis of Acalabrutinib vs Rituximab + Idelalisib or Bendamustine in Relapsed/Refractory CLL

Slideset Download
Conference Coverage
After a median follow-up of approximately 4 years, acalabrutinib maintained significantly improved PFS with no new safety concerns vs standard-of-care regimens in patients with relapsed/refractory CLL.

Released: June 09, 2022

Expiration: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab